Suppr超能文献

手术与监测治疗分化良好、无功能性胰腺神经内分泌肿瘤:国家癌症数据库 11 年分析。

Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database.

机构信息

Department of Hematology/Oncology, Stephenson Cancer Center, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.

Department of Medicine, Roswell Park Comprehensive Cancer, University of Buffalo, Buffalo, New York, USA.

出版信息

Oncologist. 2020 Feb;25(2):e276-e283. doi: 10.1634/theoncologist.2019-0466. Epub 2019 Oct 2.

Abstract

BACKGROUND

Pancreatic neuroendocrine tumors (panNETs) are a rare group of tumors that make up 2%-3% of pancreatic tumors. Recommended treatment for panNETs generally consists of resection for symptomatic or large asymptomatic tumors; however, optimal management for localized disease is still controversial, with conflicting recommendations in established guidelines. Our study aim is to compare surgical intervention versus active surveillance in nonmetastatic panNETs by size of primary tumor.

MATERIALS AND METHODS

Using the National Cancer Database, we identified 2,004 patients diagnosed with localized well-differentiated, nonfunctional panNETs (NF-panNETs) between 2004 and 2015. Patients' clinicopathologic characteristics, treatment modalities, and overall survival (OS) were analyzed using frequency statistics, chi-square, and Kaplan-Meier curves. The objective of the study is to assess the outcome of surgical resection versus nonoperative management in patients with panNETs with different tumor sizes.

RESULTS

Tumor sizes were divided into three categories: <1 cm, 1-2 cm, and >2 cm. The number of patients with tumor size <1 cm, 1-2 cm, and >2 cm was 220 (11%), 794 (39.6%), and 990 (49.4%), respectively. Overall, 1,781 underwent surgical resection, whereas 223 patients did not. Median follow-up was 25.9 months. After adjusting for covariates, surgical resection was associated with improved OS in patients with tumor size 1-2 cm (hazard ratio [HR] = 0.37) and >2c m (HR = 0.30) but not <1 cm (HR = 2.81). Independent prognostic factors were age at diagnosis, Charlson-Deyo comorbidity score, stage, tumor location, and surgical resection. Higher tumor grade was not associated with worse OS.

CONCLUSION

Our findings suggest that active surveillance is potentially a safe approach for NF-panNETs <1 cm. Larger tumors likely need active intervention. Intermediate-grade tumors did not result in worse survival outcome compared with low-grade tumors. Future studies might consider prospective randomized clinical trials to validate our findings.

IMPLICATIONS FOR PRACTICE

The present study seeks to address the discrepancy in treatment recommendations in the management of nonfunctional pancreatic neuroendocrine tumors (NF-panNETs) by evaluating whether surgical resection is associated with improved overall survival in different tumor size groups as well as elucidating independent prognostic factors in patients with NF-panNETs. Data from the National Cancer Database were reviewed. This study's findings suggest that active surveillance is potentially a safe approach for NF-panNETs <1 cm. Larger tumors likely need active intervention. Independent prognostic factors include age at diagnosis, Charlson-Deyo comorbidity score, stage, tumor location, and surgical resection. These findings will help guide medical and surgical oncologists when formulating treatment plans for patients with small NF-panNETs.

摘要

背景

胰腺神经内分泌肿瘤(panNETs)是一种罕见的肿瘤,占胰腺肿瘤的 2%-3%。panNETs 的推荐治疗方法一般包括对有症状或大的无症状肿瘤进行切除术;然而,局部疾病的最佳治疗方法仍存在争议,既定指南中的建议相互矛盾。我们的研究目的是按原发肿瘤大小比较非转移性 panNETs 中的手术干预与主动监测。

材料和方法

利用国家癌症数据库,我们确定了 2004 年至 2015 年间 2004 例局部分化良好、无功能的 panNETs(NF-panNETs)患者。使用频率统计、卡方检验和 Kaplan-Meier 曲线分析患者的临床病理特征、治疗方式和总生存期(OS)。本研究的目的是评估不同肿瘤大小的 panNETs 患者手术切除与非手术治疗的结果。

结果

肿瘤大小分为三类:<1cm、1-2cm 和>2cm。肿瘤大小<1cm、1-2cm 和>2cm 的患者数量分别为 220 例(11%)、794 例(39.6%)和 990 例(49.4%)。总体而言,1781 例患者接受了手术切除,223 例患者未接受。中位随访时间为 25.9 个月。在调整了混杂因素后,手术切除与肿瘤大小为 1-2cm(风险比[HR] = 0.37)和>2cm(HR = 0.30)的患者的 OS 改善相关,但与肿瘤大小<1cm 的患者(HR = 2.81)无关。独立的预后因素包括诊断时的年龄、Charlson-Deyo 合并症评分、分期、肿瘤位置和手术切除。较高的肿瘤分级与较差的 OS 无关。

结论

我们的研究结果表明,主动监测对于<1cm 的 NF-panNETs 可能是一种安全的方法。较大的肿瘤可能需要积极干预。中等级别的肿瘤与低级别肿瘤相比,并未导致生存结果更差。未来的研究可能会考虑前瞻性随机临床试验来验证我们的发现。

临床意义

本研究旨在通过评估手术切除与不同肿瘤大小组患者的总生存期改善是否相关,以及阐明 NF-panNETs 患者的独立预后因素,解决非功能性胰腺神经内分泌肿瘤(NF-panNETs)治疗建议不一致的问题。对国家癌症数据库的数据进行了回顾。本研究结果表明,主动监测对于<1cm 的 NF-panNETs 可能是一种安全的方法。较大的肿瘤可能需要积极干预。独立的预后因素包括诊断时的年龄、Charlson-Deyo 合并症评分、分期、肿瘤位置和手术切除。这些发现将有助于指导医疗和外科肿瘤医生为小 NF-panNETs 患者制定治疗计划。

相似文献

2
Evaluation of Survival Following Surgical Resection for Small Nonfunctional Pancreatic Neuroendocrine Tumors.
JAMA Netw Open. 2023 Mar 1;6(3):e234096. doi: 10.1001/jamanetworkopen.2023.4096.
3
Reappraisal of a 2-cm Cutoff Size for the Management of Nonfunctional Pancreatic Neuroendocrine Tumors: A Population-Based Study.
Front Endocrinol (Lausanne). 2022 Jul 18;13:928341. doi: 10.3389/fendo.2022.928341. eCollection 2022.
6
Pancreatic Neuroendocrine Tumors (panNETs): Analysis of Overall Survival of Nonsurgical Management Versus Surgical Resection.
J Gastrointest Surg. 2017 May;21(5):855-866. doi: 10.1007/s11605-017-3365-6. Epub 2017 Mar 2.
8
Duodenal neuroendocrine tumors: Somewhere between the pancreas and small bowel?
J Surg Oncol. 2019 Dec;120(8):1293-1301. doi: 10.1002/jso.25731. Epub 2019 Oct 16.

引用本文的文献

4
Novel Surgical Initiatives in Gastroenteropancreatic Neuroendocrine Tumours.
Curr Oncol Rep. 2025 Feb;27(2):157-167. doi: 10.1007/s11912-024-01632-4. Epub 2025 Jan 25.
5
NET guidelines for white patients may not fit Asian patients.
Am J Surg. 2025 Feb;240:116116. doi: 10.1016/j.amjsurg.2024.116116. Epub 2024 Dec 1.
6
Somatostatin Analogs Versus Active Surveillance in Small Pancreatic Neuroendocrine Tumors.
Pancreas. 2025 Jul 1;54(6):e524-e529. doi: 10.1097/MPA.0000000000002425.
7
Association Between Female Sex and Better Survival in Gastroenteropancreatic Neuroendocrine Tumors.
J Surg Res. 2024 Oct;302:53-63. doi: 10.1016/j.jss.2024.07.012. Epub 2024 Jul 30.
9
Contemporary Approaches to the Surgical Management of Pancreatic Neuroendocrine Tumors.
Cancers (Basel). 2024 Apr 14;16(8):1501. doi: 10.3390/cancers16081501.
10
Race and Odds of Surgery Offer in Small Bowel and Pancreas Neuroendocrine Neoplasms.
Ann Surg Oncol. 2024 May;31(5):3249-3260. doi: 10.1245/s10434-024-14906-9. Epub 2024 Jan 31.

本文引用的文献

1
Management and surveillance of non-functional pancreatic neuroendocrine tumours: Retrospective review.
Pancreatology. 2019 Mar;19(2):360-366. doi: 10.1016/j.pan.2019.02.008. Epub 2019 Feb 18.
2
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.
J Natl Compr Canc Netw. 2018 Jun;16(6):693-702. doi: 10.6004/jnccn.2018.0056.
3
The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.
Endocr Relat Cancer. 2018 Mar;25(3):367-380. doi: 10.1530/ERC-17-0445.
7
A wait-and-watch approach to small pancreatic neuroendocrine tumors: prognosis and survival.
Oncotarget. 2016 Apr 5;7(14):18978-83. doi: 10.18632/oncotarget.7902.
10
Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study.
Ann Surg Oncol. 2016 Apr;23(4):1361-70. doi: 10.1245/s10434-015-4986-1. Epub 2015 Nov 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验